Skip to content

CLINICAL TRIALS

Click below to learn more about current Vical clinical trials for specific cancer and infectious disease applications.

Current Clinical Trials

INVESTOR INFO

NASDAQ: VICL
 
 

WELCOME TO VICAL

Vical researches and develops biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

VAXFECTIN®

Vical's proprietary Vaxfectin® adjuvant has demonstrated safety and effectiveness in a number of animal models. In July 2008, we announced preliminary clinical trial data demonstrating that Vaxfectin®-formulated DNA vaccines can safely achieve significant immune responses against H5N1 pandemic influenza in humans. References to published data are included in the Vaxfectin® Publications page.